Urodynamix Technologies Ltd. To Evaluate Strategic Alternatives

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announces that its Board of
Directors has initiated a process to review strategic alternatives including the
sale of part of or all of the Company's assets. In addition, in light of recent
changes to US reimbursement (CPT Codes) and its impact on the future US sales of
uroNIRS(TM), the Company has taken steps to enhance shareholder value by further
reducing expenditures and headcount in all departments to the minimum required
to support the uroNIRS bladder products and their worldwide customers and
distribution partners. The Company will continue to support the uroNIRS bladder
products including manufacturing capabilities, sales, technical and clinical
support. "The Board of Directors and management team are committed to maximizing
value for our shareholders" said Barry Allen, President and Chief Executive
Officer. "We believe this is the right time for us to explore our strategic
alternatives to maximize the value our investment in our technology platform
including uroNIRS(TM)."


The Company does not intend to disclose developments with respect to the
strategic review process unless and until the Board of Directors has approved a
definitive transaction or strategic option, unless otherwise required by law.


About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.